New Jersey Chapter Meeting

Presentation

DATE & TIME
Thursday, March 22, 2012
6:00 PM – 9:00 PM

TITLE
De-Risking Phase III Clinical Trial Spending

SPEAKERS
Lisa Natanson, Senior Analyst, Deloitte Recap, LLC
Larry Horowitz, Principal, Doremus Advisory Services, LLC

DESCRIPTION
At the 2011 Bio International Organization (BIO) annual meeting, Lisa Natanson (Deloitte Recap) gave a presentation on the characteristics of Phase II studies (e.g., robustness of study, quality of results) that predicted Phase III success. Her results were based on an in-depth analysis using Deloitte’s data base.

The project has now taken the next step of making the study results actionable. In this presentation, Larry Horowitz (Doremus Advisory Services) and Lisa will answer the question of how should a VP of R&D and the CFO decide whether it is worthwhile to incur the time and cost needed to do a Phase II study that improves the likelihood of Phase III success? 

For licensing executives, the answer can help determine the appropriate time to out-license or in-license a product as well as the value of such a license and its terms.

LOCATION
Basking Ridge Country Club
185 Madisonville Road
Basking Ridge, NJ  07920
www.baskingridgecc.com/direct.html

SCHEDULE
6:00 PM - 7:30 PM
Cocktail Reception, Open Bar, Hors d'oeuvres, Carving Station and Light Buffet

7:30 PM - 9:00 PM
Program, Coffee & Dessert

Dress Code: Business or Business Casual

ONLINE REGISTRATION
Early by: March 21
LES Member:              $40
LES Non-member:      $45
LES Student Member: $25

Regular & Onsite
LES Member:             $50
LES Non-member:      $55
LES Student Member: $25

Registration will include a networking cocktail reception with open bar, hors d'oeuvres, carving station, light buffet, coffee and dessert.

Online Registration Deadline: Wednesday, March 21, 12 PM EST

CANCELLATION POLICY
No refunds after March 21
Substitutions are permitted

SPEAKER BIOS
Lisa Natanson
Lisa Natanson is a Senior Analyst at Deloitte Recap LLC and has worked in or written about the biotechnology industry since 1988. As product developer at Recombinant Capital, Inc. (prior to its 2008 acquisition by Deloitte), she designed and built a database tracking the clinical histories of more than 2,000 biotechnology company-originated compounds. She devised a unique data categorization process -- including discrete capture of trial outcomes and advancement decisions - in order to provide key decision makers with highly curated data to promote operational excellence in the drug development process.

Before joining Recombinant Capital in 2002, Lisa spent a decade writing articles about the biotech industry first as both Washington Editor and Business Editor of BioWorld Today and then as a freelance journalist. She founded the BioWorld financial publication, BioWorld Insight (formerly known as BioWorld Financial Watch) and conceived and designed The BioWorld Executive Compensation Report, still published today in its original reporting format. Prior to her work as a journalist, Lisa was Manager of Marketing Communications at Berkeley-based Xoma Corp. and participated in the preparation and presentation of clinical data for the murine monoclonal antibody, E5, for Gram-negative sepsis and the immunoconjugate, CD5-Plus, for graft-versus-host disease at two FDA Advisory Committee meetings in 1991.

Lisa holds a masters degree from Columbia University and a BA from the University of California. While a graduate student at Columbia, Lisa worked as an intern at Newsweek International.

Lawrence Horowitz
Lawrence Horowitz is Principal at Doremus Advisory Services, LLC, where he specializes in providing valuation in  support of R&D portfolio analysis, transaction structuring, and fund raising. He has also served as an expert
witness in the assessment of damages in breach of contract litigation.

Prior to Doremus Advisory Services, he was principal with HVA which advised private and small cap life-sciences companies on their business development transactions. Larry’s corporate experience includes Vice President of Development at C.R. Bard and Senior Director Business Development – American Cyanamid Company (acquired by American Home Products and now part of Pfizer).

Larry has taught courses in life-science entrepreneurship and financial analysis of R&D investment for Rutgers Center for Management Development and at the Umea Biotech Incubator (University of Umea, Sweden). He is the author of Leveling the Playing Field – A Guide to Successful Business Development Transactions for Private and Small Public Life SciencesCompanies and the co-author of Patent Strategies Create Value in Life Science Business Development and M&A Transactions published in IP Today, July 2009. Larry gave a Campbell Series Lecture, Choosing the Right Strategic Partner, at Rutgers Graduate School of Business.

Larry has an MBA in Finance from Columbia Graduate School of Business and a BA in Mathematics from Rutgers College.

MEETING CONTACTS

Online Registration
chapters@les.org

Event & Location
Linda Webb
New Jersey Chapter Chair
lindawebb@definedhealth.com
(973) 292-5001 Ext. 232